Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

BACKGROUND: This phase 1b study assessed the maximum tolerated dose (MTD), safety, and pharmacokinetics of motesanib (a small-molecule antagonist of VEGF receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) administered once daily (QD) or twice daily (BID) in combination with erl...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kotasek, Dusan, Tebbutt, Niall, Desai, Jayesh, Welch, Stephen, Siu, Lillian L, McCoy, Sheryl, Sun, Yu-Nien, Johnson, Jessica, Adewoye, Adeboye H, Price, Timothy
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2011
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3161034/
https://ncbi.nlm.nih.gov/pubmed/21791058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-313
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky